EP3402471A4 - Kombinationstherapie aus transclomiphen und progesteronrezeptorantagonist zur behandlung von hormonabhängigen erkrankungen - Google Patents

Kombinationstherapie aus transclomiphen und progesteronrezeptorantagonist zur behandlung von hormonabhängigen erkrankungen Download PDF

Info

Publication number: EP3402471A4
Authority: EP; European Patent Office
Prior art keywords: clomiphene; trans; receptor antagonist; combination therapy; progesterone receptor
Prior art date: 2016-01-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17738825.3A

Other languages

English (en)

French (fr)

Other versions

EP3402471A1 (de

Inventor

Joseph S. Podolski

Greg FONTENOT

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Repros Therapeutics Inc

Original Assignee

Repros Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-12

Filing date

2017-01-11

Publication date

2019-08-28

2017-01-11 Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc

2018-11-21 Publication of EP3402471A1 publication Critical patent/EP3402471A1/de

2019-08-28 Publication of EP3402471A4 publication Critical patent/EP3402471A4/de

Status Withdrawn legal-status Critical Current

Links

229940123788 Progesterone receptor antagonist Drugs 0.000 title 1
238000002648 combination therapy Methods 0.000 title 1
230000001419 dependent effect Effects 0.000 title 1
229940088597 hormone Drugs 0.000 title 1
239000005556 hormone Substances 0.000 title 1
GKIRPKYJQBWNGO-QPLCGJKRSA-N zuclomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-QPLCGJKRSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP17738825.3A 2016-01-12 2017-01-11 Kombinationstherapie aus transclomiphen und progesteronrezeptorantagonist zur behandlung von hormonabhängigen erkrankungen Withdrawn EP3402471A4 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662277782P	2016-01-12	2016-01-12
PCT/US2017/012920 WO2017123577A1 (en)	2016-01-12	2017-01-11	Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions

Publications (2)

Publication Number	Publication Date
EP3402471A1 EP3402471A1 (de)	2018-11-21
EP3402471A4 true EP3402471A4 (de)	2019-08-28

Family

ID=59311618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17738825.3A Withdrawn EP3402471A4 (de)	2016-01-12	2017-01-11	Kombinationstherapie aus transclomiphen und progesteronrezeptorantagonist zur behandlung von hormonabhängigen erkrankungen

Country Status (3)

Country	Link
US (1)	US20190008804A1 (de)
EP (1)	EP3402471A4 (de)
WO (1)	WO2017123577A1 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008067086A2 (en) *	2006-10-24	2008-06-05	Repros Therapeutics Inc.	Compositions and methods for suppressing endometrial proliferation
WO2014070517A1 (en) *	2012-11-02	2014-05-08	Repros Therapeutics Inc.	Methods and compositions for treating progesterone-dependent conditions
WO2014197477A1 (en) *	2013-06-05	2014-12-11	Repros Therapeutics Inc.	Trans-clomiphene and its analogues as agents that increase bone mineral density

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040082557A1 (en) *	2001-01-26	2004-04-29	Wajszczuk Charles Paul	Methods for treating estrogen-dependent disorders
DE602004026173D1 (de) *	2003-04-29	2010-05-06	Gen Hospital Corp	Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP1624848A4 (de) *	2003-05-02	2009-02-25	Duramed Pharmaceuticals Inc	Verfahren zur hormonbehandlung mit kontrazeptva-schemata mit verlängertem zyklus
JP6170044B2 (ja) *	2011-07-20	2017-07-26	エフ．カイザー，パトリック	薬物送達のための膣内デバイス
UA113291C2 (xx) *	2011-08-04	2017-01-10		Метаболіти транскломіфену і їх застосування
DE102011083595A1 (de) *	2011-09-28	2013-03-28	Bayer Pharma AG	Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
FI130619B (en) *	2011-11-15	2023-12-15	Upm Kymmene Corp	Matrix for sustained delivery of bioactive agents
WO2014113693A1 (en) *	2013-01-18	2014-07-24	University Of Utah Research Foundation	Modified release osmotic pump for ph-responsive intravaginal drug delivery

2017
- 2017-01-11 WO PCT/US2017/012920 patent/WO2017123577A1/en not_active Ceased
- 2017-01-11 US US16/069,686 patent/US20190008804A1/en not_active Abandoned
- 2017-01-11 EP EP17738825.3A patent/EP3402471A4/de not_active Withdrawn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008067086A2 (en) *	2006-10-24	2008-06-05	Repros Therapeutics Inc.	Compositions and methods for suppressing endometrial proliferation
WO2014070517A1 (en) *	2012-11-02	2014-05-08	Repros Therapeutics Inc.	Methods and compositions for treating progesterone-dependent conditions
WO2014197477A1 (en) *	2013-06-05	2014-12-11	Repros Therapeutics Inc.	Trans-clomiphene and its analogues as agents that increase bone mineral density

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOIAN GANCHEV ET AL: "Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatography-electrospray ionization-tandem mass spectrometry", ANALYTICAL AND BIOANALYTICAL CHEMISTRY, SPRINGER, BERLIN, DE, vol. 400, no. 10, 1 May 2011 (2011-05-01), pages 3429 - 3441, XP019924908, ISSN: 1618-2650, DOI: 10.1007/S00216-011-5045-9 *
See also references of WO2017123577A1 *

Also Published As

Publication number	Publication date
WO2017123577A1 (en)	2017-07-20
US20190008804A1 (en)	2019-01-10
EP3402471A1 (de)	2018-11-21

Legal Events

Date	Code	Title	Description
2017-07-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-10-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-10-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-11-21	17P	Request for examination filed	Effective date: 20180810
2018-11-21	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-11-21	AX	Request for extension of the european patent	Extension state: BA ME
2019-04-17	DAV	Request for validation of the european patent (deleted)
2019-04-17	DAX	Request for extension of the european patent (deleted)
2019-08-28	A4	Supplementary search report drawn up and despatched	Effective date: 20190731
2019-08-28	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 15/18 20060101ALI20190725BHEP Ipc: A61P 15/00 20060101ALI20190725BHEP Ipc: A61K 31/138 20060101AFI20190725BHEP Ipc: A61K 31/573 20060101ALI20190725BHEP Ipc: A61K 31/567 20060101ALI20190725BHEP Ipc: A61K 9/00 20060101ALI20190725BHEP Ipc: A61P 35/00 20060101ALI20190725BHEP Ipc: A61P 5/24 20060101ALI20190725BHEP
2021-01-12	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2021-01-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2021-01-20	INTG	Intention to grant announced	Effective date: 20210104
2021-01-27	INTG	Intention to grant announced	Effective date: 20210113
2021-10-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2021-11-03	18D	Application deemed to be withdrawn	Effective date: 20210526

Publication	Publication Date	Title
IL272095A (en)	2020-03-31	17-alpha-21-cortexolone diesters for use in the treatment of tumors and as glucocorticoid receptor modulators
IL261548B (en)	2021-02-28	7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions
ZA201805573B (en)	2020-12-23	Selective estrogen receptor degraders and uses thereof
IL247250A0 (en)	2016-09-29	Methods and compositions for modulating estrogen receptor mutants
MX2016011636A (es)	2016-12-12	Combinaciones terapeuticas con moduladores de receptor de estrogeno.
EP3285682A4 (de)	2019-01-02	Intraorale lichttherapievorrichtungen und verfahren zu deren verwendung
EP3247708A4 (de)	2018-09-12	Verbindungen und verfahren für gezielten abbau des androgenrezeptors
SG11201800040XA (en)	2018-02-27	Mixing device with adjustment device for gap setting
IL284005A (en)	2021-07-29	Glucocorticoid receptor inhibitors
BR112016016975A2 (pt)	2017-08-08	Usos de um antagonista do receptor crf1 para o tratamento de hiperplasia adrenal congênita e para reduzir níveis de 17-ohp e acth em um paciente
GB201506851D0 (en)	2015-06-03	Apparatus and method for providing hyperthermia therapy
IL263218A (en)	2018-12-31	Compounds and methods for microbiotic therapy
AU2015263874B2 (en)	2020-01-30	Methods and devices for treating pelvic conditions
IL271327A (en)	2020-01-30	Compositions and methods for enhancing hyperthermic therapy
PL3495352T3 (pl)	2021-08-02	Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie
EP3214618A4 (de)	2018-04-25	Audiovorrichtung und computerlesbares programm
EP3129786A4 (de)	2018-03-14	Systeme und verfahren zur identifizierung von progesteronrezeptorsubtypen
EP3126378A4 (de)	2017-09-06	Herzstärkende steroidantagonisten und zugehörige verfahren
EP3686603A4 (de)	2021-03-17	Dosisbestimmungsprogramm und dosisbestimmungsvorrichtung
PT3645997T (pt)	2023-10-26	Método e dispositivo para controlar instrumento de preparação de composição de deteção
IL272922A (en)	2020-04-30	Methods and preparations for the treatment of cone-retinal dystrophy
EP3221531A4 (de)	2018-04-04	Verankerungsvorrichtung und verfahren zur installation
PL3040486T3 (pl)	2019-09-30	Urządzenie do mocowania i poziomowania armatury sanitarnej na ścianach
SG10201607992UA (en)	2018-02-27	Method, Device and Application for Providing Authentication Service of Non-Repudiation
EP3180085A4 (de)	2018-06-27	Mittel und verfahren zur gezielten röntgenstrahlentherapie